Approval · Notice of Compliance 27451 · 2022

SOHONOS: Notice of Compliance 27451

Issued January 21, 2022

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 27451
Date: January 21, 2022
Company: Ipsen Biopharmaceuticals Canada IncMississauga, Ontario, Canada
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Priority-NAS

Products in this notice

Brand	DIN	Status today
SOHONOS	02524627	Marketed
SOHONOS	02524635	Marketed
SOHONOS	02524643	Marketed
SOHONOS	02524651	Marketed
SOHONOS	02524678	Marketed

Medicinal ingredients

PALOVAROTENE 1 MG per CAP
PALOVAROTENE 1.5 MG per CAP
PALOVAROTENE 2.5 MG per CAP
PALOVAROTENE 5 MG per CAP
PALOVAROTENE 10 MG per CAP